---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-032777"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-07-10T12:00:24+00:00"
generated_at: "2026-07-10T12:05:21.244215+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharmaceuticals reports positive preclinical results for MIRA-55 oral formulation for chronic pain

## Summary
- Selected lead oral formulation of MIRA-55 with favorable oral bioavailability and sustained systemic exposure.
- Formulation demonstrated reproducible distribution into brain and liver tissue after oral administration.
- Prior studies showed oral MIRA-55 normalized pain and reduced inflammation, outperforming injected morphine.
- MIRA-55 exhibited anxiolytic activity and no THC-like CNS effects; interacts with cannabinoid system distinct from THC.
- Company plans further preclinical evaluation of tissue exposure, pharmacodynamic activity, and therapeutic efficacy.

## SEC filing metadata
- accession: 0001493152-26-032777
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-07-10T12:00:24+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226032777/0001493152-26-032777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226032777/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-032777
- JSON: https://secwatch.observer/filing/0001493152-26-032777.json
- Plain text: https://secwatch.observer/filing/0001493152-26-032777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.